The Institute of Cancer Research (ICR), London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The ICR leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. Together with our hospital partner The Royal Marsden, we are rated in the top four centres for cancer research and treatment worldwide. As well as being a world-class institute, we are a college of the University of London. We came top in the league table of university research quality compiled from the Research Excellence Framework (REF 2014). The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.
The Cancer Research UK Cancer Therapeutics Unit (CTU), within the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 200 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The CTU’s exciting goal is to discover high quality small molecule drug candidates and to progress these to clinical trial. All the scientific disciplines are in place to make this possible, including medicinal chemistry, biology, structural biology, assay scientists, drug metabolism and clinical specialists. This is an exciting and fast-moving research setup and offers the opportunity to work within a multi-disciplinary environment using state-of-the-art techniques and equipment. A postdoctoral training fellow (PDTF) and a Higher Scientific Officer (HSO) position are available in Dr Rob van Montfort’s Hit Discovery and Structural Design Team within the CTU as part of our new Centre for protein degradation (See: https://www.icr.ac.uk/news-archive/new-centre-targets-undruggable-cancers-after-major-donation). The Post-doc (position ID185) will be involved in the structure determination of protein complexes by cryo-electron microscopy (cryoEM) as part of a CTU research programme focused on targeted protein degradation. The postholder will be responsible for sample preparation, structure determination by cryoEM and subsequent structural analysis of protein complexes. The successful candidate will be an integral member of a multidisciplinary project team within the CTU at the ICR Sutton site, and will interact closely with biologists, computational chemists, medicinal chemists assay scientists and structural biologists. The successful candidate will also be part of the Division of Structural Biology, located in Chelsea, in which the structural biologists in Dr van Montfort’s team are embedded, and will have access to its state-of-the art cryoEM facilities. These include an in-house Glacios and 30% direct access to a Titan KRIOS located at the Francis Crick Institute. Both microscopes are equipped with Falcon III detectors and volta phase plates (VPP). In addition, we have excellent access to the electron bioimaging Centre (eBIC) at the Harwell Science and Innovation campus, Didcot, UK. The postholder will be expected to work across the two sites in Chelsea, London and Sutton, Surrey. The starting salary for the PDTF position ID185 will be in the range £38,607 to £40,902 p.a. inclusive (based on previous postdoctoral experience). The Higher Scientific Officer (position ID184) will be responsible for establishing biophysical assays such as Surface Plasmon Resonance (SPR), Thermal Shift Assay (TSA) and ligand-based NMR (LO-NMR) to characterise these protein targets and their protein-protein and protein-ligand interactions. The successful candidate will be an integral member of a multidisciplinary project team and will interact closely with the biologists, computational chemists, medicinal chemists and structural biologists to help progress our drug discovery projects from hit finding to clinical trial. The starting salary for the HSO position ID184 will be in the range £32,000 to £44,400 p.a. inclusive (based on previous experience). Both posts are offered on a fixed term contract of 2 years. Informal enquiries to rob.vanmontf...@icr.ac.uk<mailto:rob.vanmontf...@icr.ac.uk> or yann-vai.lebi...@icr.ac.uk<mailto:yann-vai.lebi...@icr.ac.uk>. Please DO NOT send your application to Dr van Montfort or Dr Le Bihan, but apply via the e-recruitment system on our website www.icr.ac.uk<http://www.icr.ac.uk>. Closing date for both positions: 24 April 2022 Dr. Rob van Montfort Reader in Structural Biology and Cancer Drug Discovery Team Leader Hit Discovery and Structural Design Divisions of Cancer Therapeutics and Structural Biology The Institute of Cancer Research 15 Cotswold Road Sutton SM2 5NG UK Tel: +44-(0)20-8722-4364 Email: rob.vanmontf...@icr.ac.uk<mailto:rob.vanmontf...@icr.ac.uk> The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP. This e-mail message is confidential and for use by the addressee only. If the message is received by anyone other than the addressee, please return the message to the sender by replying to it and then delete the message from your computer and network. ######################################################################## To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB&A=1 This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list hosted by www.jiscmail.ac.uk, terms & conditions are available at https://www.jiscmail.ac.uk/policyandsecurity/
